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Abstract
Background: Subcutaneous administration of Ig (SCIg) has gained popularity as an alternative route of administration
but has never been rigorously examined in chronic inflammatory demyelinating polyneuropathy (CIDP).
Methods/design: The primary objective of the PATH study (Polyneuropathy and Treatment with Hizentra) is to
determine the efficacy of two different doses of SCIg IgPro20 (0.2 g/kg bw or 0.4 g/kg bw) in a 24-week maintenance
treatment of CIDP in comparison to placebo. The primary efficacy endpoint will be the proportion of patients who
show CIDP relapse (1-point deterioration on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT)
disability score) or are withdrawn within 24 weeks after randomization for any reason. IVIg-dependent adult patients
with definite or probable CIDP according to the European Federation of Neurological Societies/Peripheral Nerve
Society who fulfil the inclusion and exclusion criteria will be eligible. Based on sample-size calculation and relapse
assumptions in the three arms, a sample size of 58 is needed per arm (overall sample size will be 350, of which 174 will
be randomized). All eligible patients will progress through three study periods: an IgG dependency period (≤12 weeks)
to select those who are Ig dependent; an IVIg restabilization period (10 or 13 weeks), which will be performed using
the 10 % IgPro10 product; and an SC treatment period (24 weeks, followed by a 1-week completion visit after last
follow-up). Patients showing IVIg restabilization will be randomized to demonstrate the efficacy of SCIg IgPro20
maintenance treatment over placebo. After completing the study, subjects are eligible to enter a long-term, open-label,
extension study of 1 year or return to their previous treatment. In case of CIDP relapse during the 24-week SC
treatment period, IgPro10 rescue medication will be offered. Safety, tolerability, and patients’ preference of Ig
administration route will be examined.
Discussion: The PATH trial, which started in March 2012, is expected to finish at the end of 2016. The results will
increase knowledge about the efficacy, safety, and tolerability of SCIg in maintenance management of CIDP patients.
Trial Registration: ClinicalTrials.gov, NCT01545076. Registered on 1 March 2012.
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Background
Chronic inflammatory demyelinating polyneuropathy
(CIDP) is an acquired neuropathy with an assumed
autoimmune-mediated pathogenesis [1]. CIDP runs a
progressive, relapsing–remitting, or monophasic course
and can lead to significant activity limitations and par-
ticipation restrictions with a decrement in quality of life
expectations [2–4].
An estimated two thirds of patients with CIDP need
long-term treatment [5]. In a comparison of safety pro-
files, IVIg is the preferred long-term maintenance treat-
ment over corticosteroids or plasma exchange in CIDP
patients. An alternative route of Ig administration, sub-
cutaneous Ig (SCIg), has been used successfully in pa-
tients with immunodeficiency syndromes for more than
25 years [6]. SCIg infusions are well tolerated, effica-
cious, and preferred by many of these patients [7–10].
Furthermore, this route of administration increases pa-
tient compliance, autonomy, and quality of life and leads
to cost-savings [11–14]. Similar preference has been sug-
gested in patients with CIDP treated with SCIg.
The development of highly concentrated Ig prepara-
tions and special pumps to administer larger volumes
subcutaneously has also raised interest in this route of
administration for patients with inflammatory neuropa-
thies. Several case series [14–22], a relatively large, pro-
spective, observational study [23] and one small,
randomized, controlled trial [24], have reported clinical
efficacy and safety of weekly SCIg to treat CIDP. A 1-
year, open-label, follow-up study has suggested SCIg
may be used as a long-term maintenance treatment in
CIDP [25]. However, the efficacy, safety, and tolerability
of weekly SCIg in CIDP have not been studied in well-
controlled and adequately powered randomized clinical
trials. The findings of the PATH trial are expected to in-
crease the knowledge about the use of SCIg in the main-
tenance management of CIDP patients.
Methods/design
The PATH trial is a randomized, multicenter, double-
blind, placebo-controlled, parallel-group phase III study
with three arms, aiming to investigate two different
doses of SCIg IgPro20 (Hizentra®, CSL Behring, Bern,
Switzerland) for maintenance treatment of patients with
CIDP. The study began in March 2012 and is expected
to finish at the end of 2016. The trial protocol has been
approved by the ethics committees of all participating
centers (listed in the Appendix). Protocol amendments
are covered in a separate section below. The conduct of
the trial was overseen by a steering committee and an
independent data monitoring committee; committee
members are listed at the end of the manuscript. This
study is registered with ClinicalTrials.gov number
NCT01545076.
Primary objective
The primary objective is to determine the efficacy of
IgPro20 in the maintenance treatment of CIDP patients.
Secondary and exploratory objectives
 To determine the efficacy, safety, and tolerability of
IgPro20, with additional clinical outcome measures
 To determine the safety and efficacy of IVIg IgPro10
restabilization and rescue therapy
 To determine health-related quality of life (HRQL)
following treatment with IgPro20
 To explore additional safety and efficacy endpoints,




Adults (age ≥ 18 years) with definite or probable CIDP
according to the EFNS/PNS criteria may enter the trial
if they responded to IVIg treatment as assessed by the
treating physician within 8 weeks before enrollment
[26]. Written informed consent is obtained by the local
investigator before entry into the study.
Exclusion criteria
1. Any polyneuropathy of other causes, including
multifocal motor neuropathy; monoclonal
gammopathy of uncertain significance with
antimyelin-associated glycoprotein IgM antibodies;
hereditary demyelinating neuropathy; polyneurop-
athy, organomegaly, endocrinopathy, monoclonal
protein and skin change syndromes; lumbosacral
radiculoplexus neuropathy; polyneuropathy associ-
ated with diabetes mellitus; polyneuropathy associ-
ated with systemic illnesses; or drug- or toxin-
induced polyneuropathy
2. Any other disease that may cause neurological
symptoms and signs or that may interfere with
treatment or outcome assessments
3. Severe conditions that may interfere with an
evaluation of the study product or satisfactory
conduct of the study such as current malignancy or
history of allogeneic bone marrow/stem cell
transplant, cardiac insufficiency (New York Heart
Association Classes III/IV), cardiomyopathy,
significant cardiac arrhythmia requiring treatment,
unstable or advanced ischemic heart disease,
congestive heart failure or severe hypertension,
chronic kidney disease stage IV and V, known
hyperprolinemia, known bleeding disorders, severe
skin disease at the planned injection sites, alcohol,
drug or medication abuse
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4. History of thrombotic episodes within the 2 years
before enrollment, such as pulmonary embolism,
deep vein thrombosis, myocardial infarction,
thromboembolic stroke or known hypercoagulable
state
5. Known allergic or other severe reactions to blood
products including intolerance to previous IVIg,
history of hemolysis after IVIg infusion, aseptic
meningitis, recurrent severe headache,
hypersensitivity, or severe generalized skin reaction
6. Treatment with the following:
 Within 3 months before enrollment: plasma
exchange
 Within 6 months before enrollment:
cyclophosphamide, interferon, tumor
necrosis factor–alpha inhibitors, fingolimod,
or any other immunosuppressive
medications
 Within 12 months before enrollment: rituximab
or alemtuzumab
 With a change in treatment within 3 months
before enrollment: methotrexate, azathioprine, or
mycophenolate; patients on corticosteroids not
on a maintenance dose (usually below 20 mg/day
prednisone equivalent) and where the dosage is
likely to be tapered during the duration of the
trial; or patients requiring more than 1.6 g/kg IgG
every 4 weeks
7. Patients with the following laboratory results:
 Serum IgA level less than 5 % of the lower limit
of normal
 Positive result at screening on any of the
following viral markers: human
immunodeficiency virus-1 or 2, or hepatitis B or
C virus
 Abnormal laboratory parameters: creatinine
greater than 1.5 times the upper limit of normal
(ULN), blood urea nitrogen greater than three
times the ULN if the increase is related to
potential kidney disease, or hemoglobin less than
10 g/dL
8. Fulfilling the following general criteria: inability to
comply with study procedures and treatment
regimen; mental condition rendering the patient
unable to understand the nature, scope, and possible
consequences of the study; pregnancy or nursing
mother; intention to become pregnant during the
course of the study; female patients of childbearing
potential either not using or not willing to use a
medically reliable method of contraception for the
entire duration of the study or not sexually abstinent
for the entire duration of the study or not surgically
sterile; participation in another clinical study or use
of another investigational medicinal product within
3 months before enrollment; employee at the study
site; or spouse/partner or relative of any study staff
Study procedures
After being screened, all eligible patients will progress
through three study periods: an IgG dependency test
period (up to 12 weeks), an IVIg restabilization period
(10 or 13 weeks), and an SC treatment period (25 weeks;
Fig. 1).
IgG dependency test period
In this period, no IgG treatment is given. Patients are
monitored by collecting grip strength, Inflammatory-
Rasch-built Overall Disability Scale (I-RODS), and
INCAT total score data every 2 weeks, alternating by a
site visit or by phone. Any patient showing a clinically
meaningful deterioration that is confirmed by the inves-
tigator at the site will enter the IVIg restabilization
period immediately. A clinically meaningful deterior-
ation is defined as a total INCAT disability score in-
crease by ≥ 1 point, I-RODS deterioration by ≥ 4 points
(using the centile metric), or a mean grip strength de-
terioration by ≥ 8 kiloPascal (kPa) in one hand using the
handheld vigorimeter [27–30].
Patients will be instructed on how to self-assess grip
strength and I-RODS at home as part of a weekly diary.
Patients will be performing three assessments for each
hand in arbitrary order (with approximately 30 seconds
rest between each assessment) on a daily basis and at a
fixed time during the day. The mean grip strength for
each hand will be used to determine IgG dependency.
Patients who have stable disease or who show im-
provement will be asked at week 4 to delay the next IVIg
administration and to continue with self-assessment of
grip strength and I-RODS at home. Patients who do not
show signs of IgG dependency after a maximum of
12 weeks will be withdrawn from the study.
IVIg restabilization period
In this period, patients will receive IVIg IgPro10 (Privi-
gen®, CSL Behring, Bern, Switzerland) for up to 13 weeks
at the study site. The total dose/volume of IgPro10 will
be calculated based on the patient’s body weight (bw)
with a maximum of 200 g. The loading dose is 2 g/kg
(week 1) and 1 g/kg at week 4, 7, and 10 and, if neces-
sary, week 13. The infusion rates are in conformity with
the recommended rates for IgPro10 and with the market
authorization for IgPro10 (Privigen®) with a maximum of
100 g per infusion day. [31]
Only patients whose INCAT total score improves to at
least the INCAT total score recorded at the screening
visit (i.e., ≥ INCAT score at screening) and who maintain
a stable INCAT total score at weeks 7 and 10 (or at
weeks 10 and 13) are eligible for randomization. All
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other patients will not be randomized and will be with-
drawn from the study.
SC treatment period
Three-arm randomization will be performed: one group
will receive IgPro20 at 0.2 g/kg bw plus placebo to
match the volume in all three groups, one group will re-
ceive IgPro20 at 0.4 g/kg bw, and one group will receive
only placebo. The total dose/volume of IgPro20 will be
calculated on the basis of the bw. The weekly SC infu-
sion of IgPro20 or placebo will be performed on 1 or 2
consecutive days in two sessions using special infusion
pumps. Multiple injection sites and two pumps may be
used depending on the total volume to be administered.
The maximum rate is 20 mL/h in week 1, and 35 mL/h
for subsequent infusions. The maximum volume per in-
jection site is 20 mL/site in week 1 and 50 mL/site for
the subsequent infusions. Patients are advised to change
the injection site(s) with each administration.
Patients (or their caregiver) will be trained to apply SC
home therapy during the first four SC treatment sessions
at the site. If needed, up to four additional trainings will
be offered. Patients will also receive detailed written in-
structions. To ensure compliance, patients are instructed
to follow the treatment instructions carefully and to con-
tact the treating physician/study nurse to discuss any
problems with SC infusion.
Patients will bring their used, partially used, and un-
used vials of IgPro20/placebo every visit to the site.
Treatment compliance will be monitored through a drug
accountability form checking the unique vial numbers
used by a patient and the recorded infusion scheme. A
completion visit will be performed at SC week 25 for
patients who complete the SC treatment period. Patients
experiencing a CIDP relapse during the SC treatment
period will receive, within 1 week, IgPro10 as IVIg res-
cue medication (2 g/kg bw) and will undergo a comple-
tion visit before the start of the rescue medication.
Patients who withdraw for any other reason will undergo
the completion visit within a week of discontinuation.
Randomization and masking
Randomization will be controlled centrally based on a
predefined randomization schedule using block
randomization using an Interactive Web and Voice Re-
sponse System (IWRS) system maintained by an external
service provider. Randomization was stratified by for re-
gions (Japan/non-Japan). Access to the randomization
list is restricted to designated people of the service pro-
vider not involved in the conduct or analysis of the trial.
The treating physician (see below) transmits data critical
for the randomization procedure via the IWRS system.
All patients and study personnel will be blinded. Stand-
ard measures will be taken for the placebo and IgPro20
to ensure adequate blinding. A “two-physician” approach
is implemented to reduce the chance of potential study
unblinding. The “treating” physician will be the primary
contact for the patient and will be responsible for all
patient-related questions, adverse event (AE) evaluation,
and for all other study-related tasks. A second “evaluat-
ing” physician will be responsible for assessment of effi-
cacy variables. The evaluating physician does not have
access to any data collected by the treating physician.
For interim analysis and ongoing risk-benefit evalua-
tions, members of the independent data monitoring
committee may need to be unblinded. Access to study
Fig. 1 Study design. Diagram explains how patients flow through the different study periods. IgG immunoglobulin G, IVIg intravenous
immunoglobulin, INCAT Inflammatory Neuropathy, Cause and Treatment
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documents containing information on IgG levels and
treatment groups will be restricted to people not directly
involved in the study.
In case of an emergency and if necessary to make an
adequate treatment decision, the blind can be broken by
the treating physician using the interactive voice/web re-
sponse system. Patients in whom the blind code has




Primary outcome is defined as the percentage of patients
who have a CIDP relapse during SC treatment or who
are withdrawn from the study during SC treatment for
any reason.
CIDP relapse is defined as a deterioration (i.e., in-
crease) by at least 1 point in the total adjusted INCAT
score during the SC treatment period visit compared
with baseline. Baseline scores are defined as the scores
assessed at the end of the IVIg restabilization period.
The INCAT disability scale ranges from 0 (healthy) to
10 (unable to make any purposeful movements with
arms or legs) [32].
Secondary outcomes
Secondary outcomes are:
1. Between-group differences of the median changes
from baseline to completion visits in INCAT score,
mean grip strength for both hands separately,
Medical Research Council (MRC) sum score, and I-
RODS
2. Time to CIDP relapse or withdrawal for any other
reason in SC treatment period
3. Time to improvement on IgPro10 restabilization
therapy (INCAT, I-RODS, and grip strength)
4. Median changes before and at the end of IgPro10
restabilization or rescue therapy in mean grip
strength, MRC sum score, I-RODS, and INCAT dis-
ability score
5. Time to improvement after CIDP relapse in the SC
treatment period with IgPro10 rescue therapy,
defined as a decrease in INCAT score back to or
below baseline value
Grip strength will be measured as described above.
MRC sum score is determined by assessing bilateral
shoulder abduction, elbow flexion, wrist extension, index
finger abduction, hip flexion, knee extension, foot dorsi-
flexion, and great toe dorsiflexion. The MRC sum score
is the sum of all 16 muscle scores and ranges from 0
(paralysis) to 80 (normal strength) [33, 34].
The I-RODS is an outcome measure that captures ac-
tivity and social participation in patients with immune-
mediated peripheral neuropathies [28]. The 24-item
questionnaire covers a wide range of tasks of daily life
that are each to be rated as “impossible to perform,”
“able to perform with difficulties,” or “easily performed.”
The summed raw score will subsequently be trans-
formed to a centile score that ranges from 0 (most se-
vere activity and social participation limitations) to 100
(no activity and social participation limitations).
Assessment schedule of primary and secondary outcome
variables
INCAT scores, grip strength, MRC sum score, and I-
RODS will be assessed at the screening visit; during the
IgG dependency test period as described above, before
IVIg infusion at weeks 1, 4, and 7; at baseline (weeks 10
or 13); at all visits during the SC treatment period, in-
cluding the completion visit; and at any unscheduled
visit.
Safety outcomes
Patient safety will be monitored throughout the study.
AEs per infusion and number and the percent of pa-
tients with AEs will be collected for IgPro20 and for
IgPro10 separately. AEs, including serious AEs, will be
documented at each site visit and additionally for Japan
at 4 weeks after last dose. Potential hemolysis will be
assessed during the phone call on day 8 of the IVIg
restabilization period. Medications will be reviewed at
each site visit as well as 4 weeks after the last dose in
Japan.
Exploratory outcomes
Nerve conduction studies will be performed in a stan-
dardized manner after appropriate warming of the ex-
tremities. An electrophysiology manual will be provided
to all participating centers describing in detail all nerve-
conduction-study procedures. Nerve conduction studies
will be performed at baseline and at the completion visit.
Quality of life will be assessed using the EuroQoL 5-
Dimension Questionnaire (EQ-5D), Treatment Satisfac-
tion Questionnaire for Medication (TSQM), and Work
Productivity and Activity Impairment Questionnaire for
General Health (WPAI-GH) [35–39]. These instruments
will be completed by the patients themselves at screen-
ing, baseline, SC week 9, and at the completion visit.
The EQ-5D is a simple, generic measure of health sta-
tus, consisting of two components: a 0 to 100 mm visual
analog scale (VAS) assessing overall health on the day of
assessment and five questions covering five health di-
mensions [39]. The TSQM (version 1.4) is a 14-item
general instrument that measures the major dimensions
of satisfaction with a medication [36]. Scores on the
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TSQM scales range from 0 (indicating poor satisfaction)
to 100 (indicating perfect satisfaction).
The WPAI-GH questionnaire was developed to meas-
ure the effect of general health and symptom severity on
work productivity and regular activities [38]. A higher
score on the WPAI-GH indicates greater impairment
and less productivity.
Patient preference for IV or SC treatment will be
assessed via a questionnaire consisting of three options:
prefer current treatment [SCIg], prefer previous treat-
ment [IVIg], and have no preference. In addition, a se-
lection of predefined reasons for their preference will be
provided. The patient preference for treatment question-
naire will be completed at SC week 9 and at the comple-
tion visit. Other exploratory outcome measures are
hematology, serum chemistry, virology assessments, vital
sign measurements, and physical examination.
Pharmacokinetic variables will be restricted to serum
IgG levels collected at the screening visit; before the first
IVIg infusions on day 1, week 1, week 4, at baseline, and
at SC weeks 9 and 17; and at the completion visit. For
patients who receive IVIg rescue medication, IgG levels
will additionally be assessed before the first infusion of
IVIg rescue medication, before the final infusion of the
loading dose, and at each subsequent maintenance dose.
Statistical analysis
Sample size
The study is powered to show that the percentage of pa-
tients having a CIDP relapse or withdrawing from the
study during the SC treatment will be statistically signifi-
cantly higher for the placebo group than for at least one
of the examined IgPro20 doses arms. A monotonic dose
response is expected with placebo ≥ IgPro20 low dose ≥
IgPro20 high dose.
The percentages of patients who reach an endpoint
(i.e., relapse or withdraw during SC treatment) will be
assumed to be 35 % for the IgPro20 high dose, 52 % for
the IgPro20 low dose, and 65 % for placebo. These num-
bers are based on the (recalculated) data of the ICE
study extension period [32], which are adopted based on
differences in the study setup. The fraction of IVIg inde-
pendent patients included is assumed to be 15 %; those
patients are believed to have a relapse rate of 10 % re-
gardless of treatment.
The exact Cochran-Armitage trend test with equally
spaced scores has been used for the sample-size calcula-
tion. With a one-sided significance level of 2.5 %, a sam-
ple size of 58 is needed in each treatment arm to achieve
a power of 90 % in an intention-to-treat analysis based
on the above assumptions. Thus, the overall sample size
will be 174 patients treated either with IgPro20 or pla-
cebo. Accounting for patients who will not pass the IgG
dependency test and IVIg restabilization period, up to
350 patients need to be screened to ensure that 174 pa-
tients are treated with IgPro20 or placebo.
General considerations
Analyses will be based on the following populations:
total set, safety data set (SDS), pre-randomization safety
data set (PSDS), intention-to-treat set (ITTS), per proto-
col set (PPS), and rescue safety data set (RSDS). A blind
data review meeting will be arranged to discuss all
protocol deviations to decide which patients will be ex-
cluded from certain analyses. A reference visit is defined
per study period, and this visit is used to assess changes
within the period using summary statistics (Table 1). All
analyses will be done using SAS® version 9.1.3 (SAS
Institute Inc., Cary, NC) or higher.
Efficacy evaluation primary outcome
The exact Cochran-Armitage trend test will be used for
the primary outcome. This comparison will be calculated
to test for superiority of at least one IgPro20 dose over
placebo at a one-sided type-I error of α = 0.025. If the
hypothesized superiority is demonstrated, one-sided
Fisher’s exact tests will be used for the subsequent com-
parisons: placebo vs. low dose IgPro20, and low dose
IgPro20 vs. high dose IgPro20.
The proportions and corresponding two-sided 95 %
Wilson-Score confidence intervals will be calculated for
each treatment group. Point estimates for the difference
in proportions and the corresponding exact two-sided
95 % confidence intervals will be calculated for all pair-
wise treatment comparisons. The primary endpoint ana-
lyses, including all sensitivity analyses (see below), will
be performed based on the ITTS and repeated for the
PPS.
Efficacy evaluation secondary outcomes
An overview of the planned analyses is provided in
Table 2. Time to improvement during the IVIg restabili-
zation period will be analyzed separately for INCAT
total score (decrease by ≥ 1 point), mean grip strength
(increase by ≥ 8 kPa), dominant/nondominant), and I-
RODS (increase by ≥ 4 points), as well as overall using
Kaplan-Meier estimates. For the overall analysis, if a
subject has multiple dates of improvement, the first will
be used. Subjects who do not record an improvement
will be censored at the date of their last visit. Analyses
will be based on the PSDS. Time to improvement after
relapse in the SC treatment period will be analyzed on
the INCAT total score using the RSDS. An overview of
all other planned secondary analyses is provided in
Table 2.
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Safety evaluation
Duration of exposure, overall exposure in patient years,
the total dose of IgPro10 or IgPro20 received, and the
number of infusions will be summarized for the three
separate study periods, using descriptive statistics. Ana-
lyses of all AEs, including deaths, serious AEs, other sig-
nificant AEs, and AEs leading to withdrawal of study
drug or to study discontinuation will be conducted on
both a patient level and an infusion level and will be
summarized for the three separate study periods, using
descriptive statistics. For SC infusions, each infusion ses-
sion will be counted separately. IV infusions adminis-
tered over more than 1 day will be counted as separate
infusions. The time to onset and duration of the most
frequent AEs will be summarized using descriptive sta-
tistics. Continuous clinical laboratory parameters
(hematology and serum chemistry) will be summarized
for the IVIg restabilization period, by visit, using descrip-
tive statistics. Likewise, values and changes will be sum-
marized for the SCIg treatment (by treatment) and IVIg
rescue period.
Sensitivity analyses
Sensitivity analyses will be performed with modified pri-
mary endpoint definitions to investigate the potential
bias due to the inclusion of dropouts without CIDP re-
lapse (patients who withdraw from the study due to any
reason other than CIDP relapse) in the primary end-
point. For each sensitivity analysis, the analysis per-
formed for the primary endpoint will be repeated,
including the exact Cochran-Armitage trend test, one-
sided Fisher’s exact tests for the pair-wise treatment
comparisons and all estimates and confidence intervals.
For the primary analysis, only patients who complete
the study without recording a relapse are considered
nonrelapsers. All other patients, including those who
withdraw for any reason other than relapse, are consid-
ered relapsers. Four sensitivity analyses will be per-
formed that assign a different status’ (relapse or
nonrelapser) to patients who are withdrawn from the
study for reasons other than efficacy (Table 3):
 Sensitivity analysis A, withdrawn patients are
considered nonrelapsers.
 Sensitivity analysis B, withdrawn patients are
considered according to withdrawal reason.
 Sensitivity analysis C, withdrawn patients are not
included in the analysis.
 Sensitivity analysis D (exploratory), withdrawn
patients will be censored at the date of their last
visit. Kaplan-Meier estimates of the probability of
having a relapse at 24 weeks will be calculated.
Between-treatment comparison will be performed
using the log-rank test for trend. When an overall
trend is demonstrated, two subsequent one-sided
comparisons will be performed using the regular
log-rank test.
Examination of subgroups
Exploratory subgroup analyses will be performed for
endpoints in the SC treatment period (Table 4). The
subgroup analysis for age group will only be conducted
if the size of the smallest group exceeds 10 patients. The
percentage of patients experiencing a CIDP relapse (or
withdrawing for any other reason) during the SC treat-
ment period within each subgroup category will be pre-
sented by treatment group.
Interim analyses
The independent data monitoring committee will be un-
blinded for a formal interim analysis based on the out-
come data of at least 60 patients at SC week 12. The
decision will be based on the outcome at 12 weeks in
the SC treatment period rather than on the outcomes.
The decision following the interim analysis will be to ei-
ther stop the study for futility or to go on as planned
and stop with the originally planned sample size.
Table 1 Definition of reference visit and last visit of study periods
Period First visit of period Reference visit(s) of period Last visit
IgG dependency Screening Prior to AMD3: INCAT. After AMD3: INCAT:
day 14 phone call I-RODS / mean grip
strength: peak value within first 4 weeks
Week 1 day 1, before start
of IVIg infusion
…or last visit before/
at withdrawal
IVIg restabilization Week 1 day 1 at start
of IVIg infusion
Week 1 day 1 at start of IVIg infusion. If not
available, last visit of IgG Dependency Period
SC week 1 before start of SC
infusion
SC treatment SC week 1 at start of
SC infusion
Baseline (week 10/13) Week 25 visit or first IVIg infusion
for rescue before IVIg infusion
IVIg rescue first IVIg infusion for
rescue at start of IVIg
infusion
First IVIg infusion for rescue at start of IVIg
infusion
Completion visit
IgG immunoglobulin G, INCAT Inflammatory Neuropathy Cause and Treatment, IVIg intravenous immunoglobulin, I-RODS inflammatory-Rasch-built overall disability
scale, SC subcutaneous
van Schaik et al. Trials  (2016) 17:345 Page 7 of 15
Study protocol amendments
During the conduct of this trial, the protocol has been
amended five times. Amendments 1 and 2 (17 Nov 2011
and 10 Dec 2012) addressed only local changes and
Amendment 5 (15 Sep 2015) was mainly to update
safety information. With Amendment 3 and 4 (12 Apr
2013 and 11 Sep 2014), the following two important
changes were implemented:
Table 2 Analyses performed at each study period for secondary outcomes, IgG levels, and health-related quality of life variables
Period (analysis set)




- Change from reference visit
- Time to first improvement on IgPro10:
Kaplan-Meier estimates
- By treatment and by treatment and subgroup:
- Descriptive statistics
- Comparison between treatments of changes from
reference visit: exact Jonckheere-Terpstra testa
- Comparisons between each IgPro20 dose group
and placebo group, and the comparison between
the two IgPro20 dose groups of changes from
reference visit: Wilcoxon rank sum testb




- Change from reference visit
- Time to improvement after CIDP
relapse with IgPro10 rescue:
Kaplan-Meier estimates
Mean grip strength (Dominant/non-dominant hand), MRC sum score, I-RODS
Overall:
- Descriptive statistics
- Change from reference visit
- Time to first improvement on IgPro10:
Kaplan-Meier estimates
By treatment and by treatment and subgroup:
- Descriptive statistics
- Comparison between treatments of changes from
reference visit; exact Jonckheere-Terpstra testa
- Comparisons between each IgPro20 dose group
and placebo group, and the comparison between
the two IgPro20 dose groups of changes from
reference visit; Wilcoxon rank sum testb
Overall:
- Descriptive statistics
- Change from reference visit
Electrophysiological parameters (average distal latency, average proximal latency, overall average conduction velocity, average conduction block, and
average compound muscle action potential amplitude)
By treatment and by treatment and subgroup:
- Descriptive statistics
- Change from reference visit
- Between-treatment comparisons of the changes




- Change from reference visit
By treatment and by treatment and subgroup:
- Descriptive statistics
- Change from reference visit
Overall:
- Descriptive statistics
- Change from reference visit





- Change from reference visit
- Comparison between treatments of changes from
reference visit; exact Jonckheere-Terpstra testa
- Comparisons between each IgPro20 dose group
and placebo group, and the comparison between
the two IgPro20 dose groups of changes from
reference visit; Wilcoxon rank sum testb
Overall:
- Descriptive statistics
Patient preference for treatment questionnaire
By treatment:
- Descriptive statistics
EQ-5D EuroQoL 5-Dimension Questionnaire, IgG immunoglobulin G, ITTS intention-to-treat set, IVIg intravenous immunoglobulin, MRC Medical Research Council,
PSDS pre-randomization safety data set, I-RODS Inflammatory-Rasch-built Overall Disability Scale, RSDS, rescue safety data set, SC subcutaneous, TSQM Treatment
Satisfaction Questionnaire for Medication, WPAI-GH Work Productivity and Activity Impairment Questionnaire for General Health
aExact Jonckheere-Terpstra test see ref [54]
bFor each pair-wise comparison, the one-sided p value from the Wilcoxon rank sum test and the Hodges-Lehmann estimate of the median difference between
treatments will be presented together with the corresponding two-sided 95 % Moses confidence interval
cOverall between-treatment comparison will be performed using the log-rank test for trend, all pair-wise comparisons will be performed using the log-rank test
dTreatment and region (Japan, non-Japan) will be used as explanatory variables. Within the framework of this ANOVA model, comparisons of each IgPro20 dose
with placebo, and the comparison of the two IgPro20 doses will be performed. For these comparisons, the least squares mean for each treatment group, an
estimate of the difference between treatments (if applicable), corresponding 95 % confidence interval and 2-sided p-values will be presented
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(1) The IVIg withdrawal phase was modified to an IgG
dependency test and additional deterioration criteria
were implemented as described above. Fulfillment on
one of these criteria, in the event of an unchanged
INCAT score, qualified the patient to move to the next
study phase (Amendment 3). Relapse rates in the
IgPro20 groups were anticipated to increase after this
change due to the fact that significant decrease in grip
strength (i.e., 8-point deterioration) is not always accom-
panied by a corresponding worsening in adjusted
INCAT score by 1 point [40]. To correct for the new as-
sumptions for relapse percentages underlying the power
calculation, the sample size was increased from 150 to
174, and the screening numbers were increased from
250 to 350. The underlying assumptions were that 90 %
of subjects would be recruited after Amendment 3 and
the dropout rates for placebo subjects would increase to
15 % (while being around 10 % in the active treatment
groups).
(2) The length of time required for prestudy IVIg has
been reduced to 8 weeks (Amendment 4). The change in
this requirement is not expected to adversely affect the
outcomes of the SC treatment period because all pa-
tients must show IgG dependency (up to 12 weeks) and
IVIg restabilization (up to 13 weeks) before
randomization and start of SC treatment.
Data management and auditing
Data were entered directly into the Medidata Rave ®
eCRF by study sites. eCRF access for data entry was only
given to site personnel. Data generated throughout the
study were monitored, and the eCRFs were checked
against the subject records for completeness and accur-
acy. This function was completed by a CRO with defined
delegated responsibility.
Following completion of the eCRFs, the data were
checked electronically for consistency and plausibility.
Queries were generated for questionable data. All queries
Table 3 Overview of sensitivity analyses
Withdrawal reasons Assignment of patients in:
Primary analysis Sensitivity analysis
A B C Da
The patient experiences a CIDP relapse during the SC treatment
period (lack of efficacy)
Relapser Relapser Relapser Relapser Relapser
The investigator advises that the patient’s safety or wellbeing
could be compromised by further participation in the study
(physician decision)
Relapser Non-relapsers Relapser Not used for
analysis
Censored
The patient receives prohibited medication (protocol violation) Censored
Other withdrawal reason (other, adverse event, death, lost to
follow-up, protocol violation, study termination by sponsor,
and withdrawal by patient)
Non-relapsers Censored
Patient continues to study end Non-relapsers Non-relapsers Non-relapsers Non-relapsers Non-relapsers
CIPD chronic inflammatory demyelinating polyneuropathy, SC subcutaneous
aExploratory sensitivity analysis
















Sex (male/female) X X X X X X
Age group (≥18 years to≤ 65 years,
and > 65 years)
X X X X X X
Prestudy IVIg treatment modality
(IVIg maintenance therapy, acute
IVIg therapy)a
X X X X X X
Region (Japan/non-Japan) X X
Relapse status (yes/no) X
IVIg Dependency criterion: I-RODS
or grip strength
Xb
IgG immunoglobulin G, INCAT Inflammatory Neuropathy Cause and Treatment, IVIg intravenous immunoglobulin, MRC Medical Research Council, I-RODS
Inflammatory-Rasch-built Overall Disability Scale
aFor Japanese subjects only
bThis subgroup analysis will only be conducted if the group size is ≥ 30
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had to be resolved in a timely manner by the investigator.
For this purpose, data cleaning status reports have been
generated on an ongoing basis. In addition, the reconcili-
ation of all external data against the eCRF took place to
assure data consistency between the systems. On top of
this, selected tables, figures, and listings (TFLs) were gener-
ated by Chiltern Stats for clean data review. Three clean
data slices were scheduled according to the enrolment rate.
All study data, irrespective of the medium in which
they are stored, will be handled in strictest confidence in
accordance with applicable data protection laws: e.g., the
European Data Protection Directive [95/46/EC] and the
US Health Insurance Portability and Accountability Act
[HIPAA]), and will be evaluated by the sponsor and/or a
competent regulatory authority in an anonymized form.
Discussion
Design
To ensure that the true treatment difference of IgPro20
compared to placebo can be determined, the present study
includes three separate periods. First, an IgG dependency
test period is included to ensure that only patients are
treated who are still in need of IgG. The necessity of in-
cluding a run-in period in which the IVIg dose is reduced
or withheld to prove IgG dependency has become clear
during the RMC-trial [41]. Next is the IVIg restabilization
period, which will be performed with the 10 % IVIg prod-
uct IgPro10 to ensure standardized IVIg restabilization
conditions before initiation of placebo-controlled, ran-
domized, SC treatment with IgPro20 or placebo.
Finally, eligible patients will be randomized to show
that IgPro20 can maintain the improvement in INCAT
score achieved during the IVIg restabilization period in
patients with CIDP.
Selected doses
The IVIg loading dose and maintenance doses every
3 weeks for the restabilization period is based on the
EFNS/PNS Guidelines and evidence from a large inter-
national study [26, 32]. For the SC treatment period, an
equal activity of SCIg and IVIg is assumed. Furthermore,
several smaller studies in CIDP and in MMN suggest ef-
ficacy of SCIg with dosages from 0.09 to approximately
4 g/kg bw [15, 16, 22, 42]. Therefore, two doses are
being tested in this study: a lower dose with putative ac-
ceptable efficacy and a dose significantly above the lower
SCIg dose and above the weekly equivalent of the rec-
ommended IVIg dose (0.33 g/kg bw) but still within
acceptable volumes to be infused at weekly intervals.
Appropriateness of measurements
For the diagnosis of CIDP in this study, the most re-
cent guideline from the EFNS/PNS society will be
used [26]. These criteria are well accepted in the
neurological community for the diagnosis of CIDP.
Well-established and accepted outcome measures are
used to assess limb disability (INCAT score), muscle
strength (MRC sum scores), and tests of actual grip
strength. INCAT and MRC sum scores have been
widely used in other studies and publications (INCAT
[27, 43, 44]; MRC score [32, 45–48]). The adjusted
INCAT score is applied throughout the study because
changes in the function of the upper limbs from 0
(normal) to 1 (minor symptoms) or from 1 to 0 are
not considered by regulatory agencies to be clinically
significant in all patients [32].
Grip strength has been found to be significantly asso-
ciated with arm disability values over time, implying that
grip strength can be applied as an index of arm function
recovery in patients with immune-mediated polyneuro-
pathies [29, 40, 49]. The I-RODS is currently the only
linearly weighted activity and social participation limita-
tion scale. The I-RODS captures a very broad range of
difficulty items and has successfully been validated
against the Overall Disability Sum Score with an intra-
class correlation coefficient of 0.85 and a very high test
reliability of repeated measurements with an intraclass
correlation coefficient of 0.97–0.99 [28]. The I-RODS re-
sponsiveness in CIDP has recently been demonstrated
[50]. Nerve conduction studies provide objective and re-
liable indices of the integrity and function of peripheral
nerves independent of patient cooperation. They are
often included in clinical studies that evaluate treat-
ments for peripheral neuropathy to assess and/or con-
firm the efficacy of treatment [51–53]. In the situation
of IgG withdrawal, electrophysiological parameters have
not been determined before. All quality of life measures
(EQ-5D, TSQM, and WPAI) have been extensively vali-
dated in numerous therapeutic areas and have been
shown to be robust based on sensitivity, reliability, and
internal consistency [39].
For the comparison of different treatments, an assess-
ment of the patient’s preference, which will be done with
a Patient Preference for Treatment Questionnaire, is im-
portant. The safety measures used in this study (AEs,
vital signs, physical and neurological examinations, la-
boratory investigations, and viral safety) are routine pro-
cedures for clinical studies. All other efficacy and safety
measurements used in the current study are also widely
used and generally recognized in the medical literature
as relevant in the clinical evaluation of Ig therapy.
As the study involved many centers throughout the
world, special attention was given to the standardization
of outcome measures. Investigator meetings with dedi-
cated training, on-site training, and web-based trainings
were all mandatory for investigators. Central eligibility
checks and strict monitoring protocols were added to
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the standardization. All patient questionnaires were pro-
vided in the local language of the specific country and
were validated for that language.
The findings of this trial will increase knowledge
about the use of SCIg in the maintenance manage-
ment of CIDP patients and add another treatment
modality to the armamentarium of neurologists to
choose from when treating these patients. The ex-
pected benefits of weekly SCIg are a reduction in sys-
temic AEs and an increase in patient autonomy and
quality of life through self-treatment. High IgG peak
levels and low trough levels are avoided, and a more
constant IgG level is achieved. This is expected to re-
sult in a reduced wear-off effect at the end of the
dosing period.
Trial status
The trial started in March 2012 and completed pa-
tient recruiting by the end of November 2015. Cur-
rently, 289 patients have been screened, and 172 have
been randomized. Study completion is expected at the
end of 2016.
All items from the World Health Organization Trial
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